Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694239 | 1.00 | ACHE (0.50) | ACHETSHRALDH1A1CA1CA2 | |
| SCHEMBL16694400 | 1.00 | ACHE (0.50) | ACHETSHRALDH1A1CA1CA2 | |
| SCHEMBL16865535 | 0.85 | ACHE (0.38) | ACHETSHRALDH1A1CA1CA2 | |
| SCHEMBL16865534 | 0.85 | ACHE (0.38) | ACHETSHRALDH1A1CA1CA2 | |
| SCHEMBL16865527 | 0.85 | ACHE (0.38) | ACHETSHRALDH1A1CA1CA2 | |
| SCHEMBL11187053 | 0.84 | TSHR (0.57) | ACHETSHRALDH1A1KMT2ANPSR1 | |
| SCHEMBL31454659 | 0.84 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1CYP1A2KMT2ANPSR1 | |
| SCHEMBL30601748 | 0.84 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1CYP1A2KMT2ANPSR1 | |
| SCHEMBL28374154 | 0.84 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1CYP1A2KMT2ANPSR1 | |
| SCHEMBL11803543 | 0.84 | CYP1A2 (0.50) | TSHRALDH1A1L3MBTL1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076359-A1 | A PROCESS FOR MAKING ENOL ETHERS | EASTMAN CHEMICAL COMPANY (US) | 2022-04-14 | — | — | WO | claimed |
| US-11518899-B2 | Aromatic enol ether paint additives | EASTMAN CHEMICAL COMPANY (US) | 2022-12-06 | — | — | US | disclosed |
| WO-2022076359-A1 | A PROCESS FOR MAKING ENOL ETHERS | EASTMAN CHEMICAL COMPANY (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021046040-A1 | AROMATIC ENOL ETHER PAINT ADDITIVES | EASTMAN CHEMICAL COMPANY (US) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046006-A1 | AROMATIC ENOL ETHERS | EASTMAN CHEMICAL COMPANY (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20210062031-A1 | AROMATIC ENOL ETHER PAINT ADDITIVES | EASTMAN CHEMICAL COMPANY (US) | 2021-03-04 | — | — | US | disclosed |
| US-10858304-B1 | Aromatic enol ethers | EASTMAN CHEMICAL COMPANY (US) | 2020-12-08 | — | — | US | disclosed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| CN-101553474-A | Imidazolidinone and imidazolidinone derivatives as 11 b-HSD 1 inhibitors for diabetes | HOFFMANN LA ROCHE (CH) | 2009-10-07 | — | — | CN | disclosed |
| CN-1703401-A | Substituted 1-benzyl-4-arylpiperazine analogs as ligands for melanin concentrating hormone receptors | NEUROGEN CORP (US) | 2005-11-30 | — | — | CN | disclosed |
| US-6114582-A | DECYCLIZATION TO FORM A CHEMICAL INTERMEDIATE FOR PRODUCING AN ANTI-OBESITY AGENT AND ANTIDIABETIC AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-05 | — | — | US | disclosed |
| US-5811293-A | CULTURE PRODUCT AS CHEMICAL INTERMEDIATE FOR ANTI-OBESITY AGENT | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-22 | — | — | US | disclosed |
| US-5629200-A | MICROORGANISM | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| US-4364952-A | Certain 1,4-dihydro-2,6-dimethyl-3,5-pyridine-dicarboxylates, composition containing same and method of use | BAYER AKTIENGESELLSCHAFT (DE) | 1982-12-21 | — | — | US | disclosed |
| EP-0042093-A2 | 4-Aralkyl-1,4-dihydropyridines, processes for praparing them, their use as medicines and preparation thereof | BAYER AG (DE) | 1981-12-23 | — | — | EP | disclosed |
| US-4068070-A | ANGINA PECTORIS | FUJI CHEMICAL INDUSTRY CO., LTD. (JA) | 1978-01-10 | — | — | US | disclosed |
| US-3962247-A | ANGINA PECTORIS | FUJI CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-06-08 | — | — | US | disclosed |
| US-3948899-A | CEREBRAL AND CORONARY CIRCULATION | FUJI CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858304-B1 | Aromatic enol ethers | ETV1, ENO1, MYB | ACHE 908/4885TSHR 4494/4885ALDH1A1 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.